Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Report Extensive Analysis 2019 | Specified by Production, Technology, Competition, and Revenue Forecast till 2024

Sodium-dependent

The “Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market” 2019 provides an in-depth analysis of all market dynamics including drivers and restraints, and trends and opportunities. Important factors supporting growth across various is also provided. The impact of prevailing regulatory scenario on both regional and worldwide Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market is provided in detail in the report. Industry Research offers an extensive collection of reports on different markets covering crucial details. The report studies the competitive environment of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market is based on company profiles and their efforts on increasing product value and production.

Market Overview:

  • The SGLT2 inhibitors class of drugs include Jardiance, Fraxiga, Inovokana, and Suglat, among others. The demand for SGLT2 is expected to grow immensely, due to drugs like Jardiance and Farxiga.
  • The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. The global SGLT2 market has a high potential for growth, due to the increasing number of diabetic patients and their need for drugs that help reduce high blood glucose levels, despite being on a medication regimen, such as metformin and insulin. SGLT2 serves this specific purpose.
  • The global market for SGLT2 is worth USD 6,573.8 million in 2019 and is expected to grow at CAGR of 16% by 2024.

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999739

    Some of The Major Key Players of Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Are:

  • Eli Lilly
  • Janssen Pharmaceuticals
  • Astellas
  • Boehringer Ingelheim
  • AstraZeneca
  • Bristol Myers Squibb

    Scope of the Report:

  • The report includes a complete study of SGLT2 inhibitors, which include Invokana, Jardiance, Farxiga, and Suglat. The study is further divided into regional- and country-wise analyses, which cover all the drugs in the SGLT2 class.

    Market Dynamics: –

    • Drivers: (Developing regions and growing markets)
    • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
    • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

    The report provides key statistics on the market status of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Sodium-dependent Glucose Co-transporter 2 (SGLT 2).

    For More Information or Query or Customization Before Buying, Visit athttps://www.industryresearch.co/enquiry/pre-order-enquiry/13999739

    Key questions answered in the report include:

    • What will the market size and the growth rate be in 2024?
    • What are the key factors driving the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market?
    • What are the key market trends impacting the growth of the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market?
    • What are the challenges to market growth?
    • Who are the key vendors in the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market?
    • What are the market opportunities and threats faced by the vendors in the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market?
    • Trending factors influencing the market shares of the relevant regions.
    • What are the key outcomes of the five forces analysis of the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market?

    Key Market Trends: – Jardiance is Leading the SGLT2 Market.

    Jardiance, which was released globally in 2014, is a once-daily oral medication that is used to control blood glucose levels in people with type-2 diabetes.
    Jardince is gaining sales when compared to Invokana, with patients preferring this drug, as it has a lower risk of cardiovascular diseases when compared to other SGLT2 drugs, by helping the kidneys remove glucose from the bloodstream.
    Jardiance accounted for 41.5% of the sales in the global SGLT2 class of drugs in 2017. The market for Jardince was worth USD 2.5 billion in 2018 and is expected to grow at a CAGR of 15.78%, during the forecast period (2019-2024).

    65% of the Market Share is Occupied by North America.
    The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. North America accounts for the highest type- 2 diabetic population. Prices are comparatively high in this region.
    The North America SGLT2 market accounts for USD 3,471.5 million in 2018 and is expected to grow at CAGR of 15.5% by 2024.
    In the United States, there are close to 900 lawsuits currently pending, regarding Invokana. Jardiance holds 50% of the market share in the US SGLT2 market.

    Purchase this Report (Price 5000 USD for single user license) – https://www.industryresearch.co/purchase/13999739

    Study objectives of Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Report:

    • To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market
    • To provide insights into factors influencing and affecting market growth
    • To provide historical, current, and forecast revenue of market segments based on material, type, design, and end user
    • To provide historical, current, and forecast revenue of market segments and sub-segments with respect to regional markets and key countries
    • To provide strategic profiling of key players in the market, comprehensively analyzing their market shares, core competencies, and drawing a competitive landscape for the market
    • To provide economic factors, technology trends, and market trends that influence the global Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market

    Detailed TOC of Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Sodium – Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
    5.1.1.1 Invokana (Canagliflozin)
    5.1.1.2 Jardiance (Empagliflozin)
    5.1.1.3 Farxiga/Forxiga (Dapagliflozin)
    5.1.1.4 Suglat (Ipragliflozin)
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume 2012-2024)
    5.2.1.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2 Europe
    5.2.2.1 France (Value and Volume 2012-2024)
    5.2.2.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.2 Germany (Value and Volume 2012-2024)
    5.2.2.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.3 Italy (Value and Volume 2012-2024)
    5.2.2.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.4 Spain (Value and Volume 2012-2024)
    5.2.2.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.5 UK (Value and Volume 2012-2024)
    5.2.2.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.6 Russia (Value and Volume 2012-2024)
    5.2.2.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.2.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume 2012-2024)
    5.2.3.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.3.2 Brazil (Value and Volume 2012-2024)
    5.2.3.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
    5.2.3.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume 2012-2024)
    5.2.4.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.2 South Korea (Value and Volume 2012-2024)
    5.2.4.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.3 China (Value and Volume 2012-2024)
    5.2.4.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.4 India (Value and Volume 2012-2024)
    5.2.4.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.5 Australia (Value and Volume 2012-2024)
    5.2.4.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.6 Vietnam (Value and Volume 2012-2024)
    5.2.4.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.7 Malaysia (Value and Volume 2012-2024)
    5.2.4.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.8 Indonesia (Value and Volume 2012-2024)
    5.2.4.8.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.9 Philippines (Value and Volume 2012-2024)
    5.2.4.9.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.10 Thailand (Value and Volume 2012-2024)
    5.2.4.10.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
    5.2.4.11.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
    5.2.5.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.2 Iran (Value and Volume 2012-2024)
    5.2.5.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.3 Egypt (Value and Volume 2012-2024)
    5.2.5.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.4 Oman (Value and Volume 2012-2024)
    5.2.5.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.5 South Africa (Value and Volume 2012-2024)
    5.2.5.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
    5.2.5.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

    6 MARKET INDICATORS
    6.1 Type-1 Diabetes Population (2012-2024)
    6.2 Type-2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Eli Lilly
    7.1.2 Janssen Pharmaceuticals
    7.1.3 Astellas
    7.1.4 Boehringer Ingelheim
    7.1.5 AstraZeneca
    7.1.6 Bristol Myers Squibb
    7.2 MARKET SHARE ANALYSIS
    7.2.1 Eli Lilly
    7.2.2 Janssen Pharmaceuticals
    7.2.3 Astellas
    7.2.4 Boehringer Ingelheim
    7.2.5 AstraZeneca

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Extraction Fans Market Size 2019: Segmentation with Manufacturers, Regions, Types, Applications, and Forecast by 2024

    Keratin Market 2019: Global Industry Overview by Size, Share, Trends, Growth Factors, Historical Analysis, Opportunities and Industry Segments Poised for Rapid Growth by 2023

    Terminal Block Market 2019: Global Industry Current Trends, Top Companies, Application, Growth Factors, Development and Forecast to 2025 Research Report

    Furniture Bolts Market 2019 Global Industry Size, Share, Demands, Growth Analysis, Company Profiles, Revenue and Forecast 2024

  • Avatar

    sambit